Bank of New York Mellon’s BIOATLA INC BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,450
Closed -$421K 4136
2024
Q1
$421K Sell
2,450
-210
-8% -$26.1K ﹤0.01% 3632
2023
Q4
$327K Hold
2,660
﹤0.01% 3763
2023
Q3
$226K Hold
2,660
﹤0.01% 3917
2023
Q2
$399K Buy
2,660
+2,260
+565% +$389K ﹤0.01% 3710
2023
Q1
$53.6K Hold
400
﹤0.01% 4186
2022
Q4
$165K Buy
400
+137
+52% +$56.8K ﹤0.01% 4023
2022
Q3
$101K Buy
+263
New +$86.1K ﹤0.01% 4194
2022
Q2
Sell
-1,015
Closed -$254K 4592
2022
Q1
$254K Hold
1,015
﹤0.01% 4108
2021
Q4
$996K Buy
1,015
+139
+16% +$178K ﹤0.01% 3390
2021
Q3
$1.29M Buy
876
+257
+42% +$501K ﹤0.01% 3249
2021
Q2
$1.31M Sell
619
-17
-3% -$38.4K ﹤0.01% 3249
2021
Q1
$1.62M Buy
+636
New +$1.63M ﹤0.01% 3048

Other funds holding BCAB

Bank of New York Mellon's BCAB Position: Q2 2024 in Review

Bank of New York Mellon sold out of BIOATLA INC (BCAB) in Q2 2024, closing a stake of 2,450 shares — an estimated $421K sold.

Bank of New York Mellon first reported a position in BCAB in Q1 2021 and held it in 12 quarters. The position peaked at $1.62M in Q1 2021. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Bank of New York Mellon reported no remaining BIOATLA INC position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 2,450 BIOATLA INC shares in Q2 2024, an estimated $421K.
  • Bank of New York Mellon first reported a position in BIOATLA INC in Q1 2021 and held it in 12 quarters.
  • Bank of New York Mellon's BIOATLA INC position peaked at $1.62M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held BIOATLA INC as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.